[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628815":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":63,"collaborators":24,"id":65,"slug":24,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":24,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":24,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Risankizumab Dose A","EXPERIMENTAL","Participants will receive Dose A of risankizumab via intravenous (IV) infusion.",[13],"Drug: Risankizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Risankizumab Dose B","Participants will receive Dose B of risankizumab via subcutaneous (SC) injection.",[13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Risankizumab","Intravenous (IV)",[9],null,{"type":20,"name":21,"description":26,"armGroupLabels":27,"otherNames":24},"Subcutaneous (SC) Injections",[15],[29],{"name":30,"affiliation":5,"role":31},"ABBVIE INC.","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",[39,53],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":24},"CenExel ACT- Anaheim Clinical Trials \u002FID# 281821","RECRUITING","Anaheim","California","92801","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.9145,33.83529,{"lat":51,"lon":50},{"facility":54,"status":41,"city":55,"state":56,"zip":57,"country":45,"countryCode":46,"cosmosGeoPoint":58,"geoPoint":62,"contacts":24},"Cpmi \u002FId# 281783","Miami","Florida","33172",{"type":48,"coordinates":59},[60,61],-80.19366,25.77427,{"lat":61,"lon":60},{"type":64,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100628815",false,"NCT07466550","A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants","A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Risankizumab","Inclusion Criteria:\n\n* Body weight between 40 kg and 100 kg inclusive at screening and upon initial confinement.\n* BMI is ≥ 18.0 to ≤ 32.0 kg\u002Fm2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* Exposure to any anti-interleukin-12\u002F23 or anti interleukin-23 treatment for at least one year prior to Screening.\n* Intention to perform strenuous exercise to which the subject is unaccustomed within one week prior to administration of first dose of study treatment or during the study.",true,"ALL","18 Years","65 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.",[83],"Healthy Volunteer",[83,21],"2026-06-29",{"date":87,"type":88},"2026-07-01","ACTUAL",{"date":90,"type":88},"2026-06-04",{"date":92,"type":77},"2027-01",{"name":5,"class":6},2]